JP7068162B6 - Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。 - Google Patents

Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。 Download PDF

Info

Publication number
JP7068162B6
JP7068162B6 JP2018503184A JP2018503184A JP7068162B6 JP 7068162 B6 JP7068162 B6 JP 7068162B6 JP 2018503184 A JP2018503184 A JP 2018503184A JP 2018503184 A JP2018503184 A JP 2018503184A JP 7068162 B6 JP7068162 B6 JP 7068162B6
Authority
JP
Japan
Prior art keywords
cells
dim
alkyl
cell population
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018503184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519845A (ja
JP7068162B2 (ja
Inventor
ストラセル カトリーヌ
ガシェ クリスチャン
ランザ フランソワ
ブルアール ナタリー
Original Assignee
エタブリスマン フランセ デュ サン
アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル
ユニベルシテ ドゥ ストラスブール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エタブリスマン フランセ デュ サン, アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル, ユニベルシテ ドゥ ストラスブール filed Critical エタブリスマン フランセ デュ サン
Publication of JP2018519845A publication Critical patent/JP2018519845A/ja
Priority to JP2021121618A priority Critical patent/JP2021177774A/ja
Publication of JP7068162B2 publication Critical patent/JP7068162B2/ja
Application granted granted Critical
Publication of JP7068162B6 publication Critical patent/JP7068162B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018503184A 2015-07-23 2016-07-22 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。 Active JP7068162B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021121618A JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1557020 2015-07-23
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
PCT/EP2016/067594 WO2017013262A1 (en) 2015-07-23 2016-07-22 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021121618A Division JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。

Publications (3)

Publication Number Publication Date
JP2018519845A JP2018519845A (ja) 2018-07-26
JP7068162B2 JP7068162B2 (ja) 2022-05-16
JP7068162B6 true JP7068162B6 (ja) 2023-12-20

Family

ID=55072774

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018503184A Active JP7068162B6 (ja) 2015-07-23 2016-07-22 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
JP2021121618A Pending JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021121618A Pending JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。

Country Status (8)

Country Link
US (3) US11236303B2 (enExample)
EP (1) EP3334822B1 (enExample)
JP (2) JP7068162B6 (enExample)
CN (1) CN107922924B (enExample)
AU (1) AU2016296920B2 (enExample)
CA (1) CA2993596A1 (enExample)
FR (1) FR3039166B1 (enExample)
WO (1) WO2017013262A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
FR3101885B1 (fr) 2019-10-11 2024-11-08 Francais Du Sang Ets Systeme pour la liberation de plaquettes et procede de liberation de plaquettes
CN115868454B (zh) * 2022-12-23 2025-09-02 中国医学科学院血液病医院(中国医学科学院血液学研究所) 基于免疫缺陷小鼠移植检测人巨核偏向造血干细胞功能方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538720A (ja) 2002-09-13 2005-12-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 哺乳動物巨核球前駆細胞
WO2009119105A1 (ja) 2008-03-28 2009-10-01 国立大学法人東京大学 ＧＰＩｂα＋ＧＰＶ＋ＧＰＶＩ＋血小板のインビトロ調製法
WO2012129109A2 (en) 2011-03-18 2012-09-27 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
US20130216506A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Bioreactor for Isolation of Rare Cells and Methods of Use
WO2014028749A2 (en) 2012-08-15 2014-02-20 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220937D0 (en) * 2012-11-21 2013-01-02 Airbus Uk Ltd Modular structural assembly
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538720A (ja) 2002-09-13 2005-12-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 哺乳動物巨核球前駆細胞
WO2009119105A1 (ja) 2008-03-28 2009-10-01 国立大学法人東京大学 ＧＰＩｂα＋ＧＰＶ＋ＧＰＶＩ＋血小板のインビトロ調製法
WO2012129109A2 (en) 2011-03-18 2012-09-27 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
US20130216506A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Bioreactor for Isolation of Rare Cells and Methods of Use
WO2014028749A2 (en) 2012-08-15 2014-02-20 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EXPERIMENTAL HEMATOLOGY，米国，ELSEVIER INC，2010年08月，VOL:38, NR:8，PAGE(S):685 - 695
HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION，イタリア，2003年04月，VOL:88, NR:4，PAGE(S):379 - 387
J. CELL. PHYSIOL.，2000年，Vol.184，PAGE(S):58-69
JOURNAL OF IMMUNOLOGICAL METHODS，2015年03月17日，VOL:423，PAGE(S):45 - 51，http://dx.doi.org/10.1016/j.jim.2015.03.002

Also Published As

Publication number Publication date
JP2018519845A (ja) 2018-07-26
CA2993596A1 (en) 2017-01-26
EP3334822A1 (en) 2018-06-20
US20240417686A1 (en) 2024-12-19
EP3334822B1 (en) 2025-10-15
US20180216068A1 (en) 2018-08-02
US11236303B2 (en) 2022-02-01
JP2021177774A (ja) 2021-11-18
JP7068162B2 (ja) 2022-05-16
AU2016296920A1 (en) 2018-02-15
WO2017013262A1 (en) 2017-01-26
CN107922924A (zh) 2018-04-17
US20220135946A1 (en) 2022-05-05
FR3039166A1 (enExample) 2017-01-27
FR3039166B1 (fr) 2018-10-26
CN107922924B (zh) 2022-01-11
AU2016296920B2 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US20240417686A1 (en) Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
Tondreau et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential
Lange et al. High-potential human mesenchymal stem cells
KR102151210B1 (ko) 규정된 조건하에서 인간 만능성 줄기 세포의 조혈내피세포 분화를 위한 방법 및 재료
Grisendi et al. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion
Park et al. In vitro neuronal and osteogenic differentiation of mesenchymal stem cells from human umbilical cord blood
US20080118477A1 (en) Umbilical cord mesenchymal stem cells support cord blood hematopoiesis
JP7522800B2 (ja) 造血移植片の改善方法
KR20100091192A (ko) 제대혈 유도된 세포와 월경 줄기 세포의 공동-배양 방법
US20250297222A1 (en) Xeno-free generation of tissue-specific progenitor cells
Stute et al. Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant
KR102320682B1 (ko) 요유래 줄기세포 배양을 위한 배지조성물 및 이를 이용한 요유래 줄기세포의 배양방법
JPH10136978A (ja) 造血幹細胞の培養方法
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
KR101149007B1 (ko) 생착능이 증가된 조혈줄기세포의 제조방법
EP1673445B1 (en) Blood products from mesenchymal stem cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210726

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211008

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220428

R150 Certificate of patent or registration of utility model

Ref document number: 7068162

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250